BRAF V600E基因突变与甲状腺乳头状癌临床病理特征的相关性  

Correlation of BRAF V600E mutation with the clinicopathological features of papillary thyroid carcinoma

作　　者：薄云峰[1] 郗彦凤[1] 于转转 李静[1] 赵园园[1] 李合 徐恩伟[1] Bo Yunfeng;Xi Yanfeng;Yu Zhuanzhuan;Li Jing;Zhao Yuanyuan;Li He;Xu Enwei(Department of Pathology, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China;Graduate School, Shanxi Medical University, Taiyuan 030001, Chin)

机构地区：[1]山西省肿瘤医院病理科,太原030013 [2]山西医科大学研究生学院,太原030001

出　　处：《肿瘤研究与临床》2018年第4期237-240,共4页Cancer Research and Clinic

摘　　要：目的探讨甲状腺乳头状癌（PTC）患者BRAF V600E基因突变率及其与临床病理特征的关系。方法收集2014年8月至2015年10月山西省肿瘤医院临床及病理资料完整的PTC患者265例，包括经典型226例，滤泡型29例，高细胞型3例，弥漫硬化型2例，嗜酸细胞型2例，囊性型3例。全部经实时荧光定量聚合酶链反应（RT-PCR）检测BRAF V600E基因突变。采用Pearson χ^2检验和Fisher确切概率法分析PTC患者基因突变与临床病理特征间的关系。结果PTC患者的BRAF V600E基因突变率为73．21％（194／265）。不同年龄、性别、肿瘤部位、肿瘤个数、被膜外侵犯患者的BRAF V600E基因突变率比较，差异均无统计学意义（均P〉0．05），而不同肿瘤最大径、病理组织学亚型、淋巴结转移、临床分期患者的BRAF V600E基因突变率比较，差异均有统计学意义（均P〈0．05）。结论BRAF V600E基因突变阳性的PTC患者具有较差的临床病理学特征，BRAF V600E基因突变可能成为预测进展型PTC患者的一项指标。Objective To discuss the BRAF V600E mutation rate in papillary thyroid carcinoma （PTC） and its relationship with the clinicopathological features. Methods Two hundred and sixty-five PTC patients （including 226 cases of classical type, 29 cases of follicular type, 3 cases of high cell type, 2 cases of diffuse sclerosis type, 2 cases of eosinophilic type, 3 cases of cystic type） from August 2014 to October in Shanxi Provincial Cancer Hospital, were collected with completely clinical and pathological information. The BRAF V600E mutation was detected by real-time polymerase chain reaction （RT-PCR） method. Pearson χ^2 test and the exact probability method were used to analysis the relationship between gene mutations and clinicopathological data. Results BRAF V600E mutation rate in PTC patients was 73.21% （194/265）. There was no significant difference in the mutation rate of BRAF V600Eamong patients with different age, gender, tumor location, tumor number and extravaginal invasion （all P 〉 0.05）, but the mutation rates of BRAF V600E gene in patients with different tumor size, histopathological subtypes, lymph node metastasis and clinical stage were significantly different （all P 〈 0.05）. Conclusion The PTC patients with positive BRAF V600E mutation have poor clinicopathological features, and BRAF V600E mutation may be a predictor of advanced PTC.

关 键 词：甲状腺肿瘤 癌 乳头状 BRAF V600E基因突变 聚合酶链反应 

分 类 号：R736.1[医药卫生—肿瘤]